University of Connecticut

OpenCommons@UConn
Master's Theses

University of Connecticut Graduate School

5-12-2019

Medication Adherence in Pediatric Asthma: A
Preliminary Analysis of a Randomized Control
Trial using Electronic Monitoring Devices
Ye Sun
yesun@uchc.edu

Recommended Citation
Sun, Ye, "Medication Adherence in Pediatric Asthma: A Preliminary Analysis of a Randomized Control Trial using Electronic
Monitoring Devices" (2019). Master's Theses. 1385.
https://opencommons.uconn.edu/gs_theses/1385

This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.

Medication Adherence in Pediatric Asthma: A Preliminary Analysis of a Randomized
Control Trial using Electronic Monitoring Devices

Ye Sun

B.S., University of Connecticut, 2014

A Thesis
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Public Health
At the
University of Connecticut
2019

Copyright by

Ye Sun

[2019]

ii

APPROVAL PAGE
Masters of Public Health Thesis
Medication Adherence in Pediatric Asthma: A Preliminary Analysis of a Randomized Control
Trial using Electronic Monitoring Devices

Presented by
Ye Sun, B.S.

Major Advisor _________________________________________________________________
Jane Ungemack, PhD

Associated Advisor _____________________________________________________________
Jessica Hollenbach, PhD

Associated Advisor _____________________________________________________________
Chia-Ling Kuo, PhD

University of Connecticut
2019

iii

Acknowledgements
I would like to thank Dr. Tregony Simoneau, Dr. Jessica Hollenbach, Christine Langton, Sigrid
Almeid, Masai McIntosh, along with everyone at the CCMC pulmonary clinic and Asthma
Center for their guidance and expertise during this project. Additionally, thank you to Dr. ChiaLing Kuo for all her guidance with statistical analysis. I would also like to thank Dr. Jane
Ungemack for all her help and support.
Lastly, thank you to my friends and family for their unwavering support.

iv

Table of Contents

INTRODUCTION …………………………………………………………………………… 1
SPECIFIC AIMS ………………..…………………………………………………………… 1
BACKGROUND ……………………………………………..……………………………… 2
METHODS …………………………………………………………………………………... 9
RESULTS…………………………………………………………………………………...…19
DISCUSSION………………………………………………………………………………….27
CONCLUSION…………………………………………………………………………...……33
REFERENCES……………………………………………………………………..…………..34

v

INTRODUCTION:
Asthma is the most common chronic disease in children, affecting more than 6.1 million
children under the age of 18 in the US (Center for Disease Control, 2015). Asthma is
characterized by persistent airway inflammation, hyper-responsiveness to bronchodilators,
reversible and variable airflow obstruction which leads to respiratory symptoms that vary in
terms of frequency and severity over time (Bonini and Usmani, 2018). Asthma is a significant
burden to the healthcare industry, resulting in 439,000 hospitalizations and 1.8 million
emergency department (ED) visits, contributing to 3,518 deaths in 2016, 209 of whom where
children (CDC, 2016). None-adherence to asthma medication is a common problem in patients
with asthma, especially in children, leading to more frequent asthma exacerbations, ED visits and
hospital admissions (McGrady and Hommel, 2013). Current methods of assessing for adherence,
including self-report and pharmacy record, often overestimate actual adherence, making them
unreliable means of supporting clinical decision making (Desai and Oppenheimer, 2011).
Electronic monitoring devices (EMDs) are more accurate means of assessing for adherence but
are not currently used in practice. The objective of this study was to determine whether a mobilebased reminder system paired with EMDs could improve pediatric asthma medication adherence.

SPECIFIC AIMS:
Pediatric with physician-diagnosed persistent asthma in the Hartford community were
recruited into this study to assess the feasibility and utility of EMD technology in this at-risk
population. It was hypothesized that by combining a mobile-based reminder system paired with
EMDs and patient education through adherence feedback, there would be an increase in
adherence to asthma medications in children with persistent asthma.

BACKGROUND Optimal asthma management is dependent on adequate control of asthma symptoms, and
prevention of exacerbations. Exacerbations require bronchodilator usage and severe
exacerbations results in treatment with systemic corticosteroids and may require hospitalization
or stays in the intensive care unit (Lasmar et al, 2009). For patients with persistent disease, where
symptoms are not relieved with inhaled beta-2 agonists (“reliever” medication) alone, the
mainstay of therapy relies on inhaled corticosteroids (ICS), also known as “preventer” or
“controller medication”. ICSs typically require daily administration to achieve adequate efficacy,
along with proper technique and regular dosage timing (Gillette et al, 2016). Adequate adherence
to ICSs has been shown to be integral in controlling asthma symptoms as well as in preventing
ED visits and hospitalizations (Barnes et al, 2015). Studies have shown that adherence rates of at
least 75% - 80% are required for adequate asthma control (Lasmar et al, 2009; Williams et al,
2011). Yet, extensive studies report suboptimal adherence rates, especially in children, where
reported rates of adherence are typically <50% (Engelkes et al, 2015; Morton et al, 2014).
Several factors have been shown to contribute to medication non-adherence, including low
socioeconomic status, low literacy, medication cost, access to care, language barriers, as well as
parent-child relationships (Bidwal et al, 2016; Burgess et al, 2011).
Poor adherence to anti-inflammatory therapy in the form of ICS is associated with
significant asthma morbidity and mortality (Milgrom et al, 2002; Milgrom et al, 1996; Cote et al,
2003). Non-adherence to asthma medication leads to overuse of reliever medication and more
frequent severe asthma exacerbations, leading to more frequent ED visits and hospital
admissions, resulting in increased healthcare utilization and cost (Puranik et al, 2016, McGrady
and Hommel, 2013). Additionally, children with poor adherence are more likely to have
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worsened lung function (Morton et al, 2014). A recent report from the United Kingdom
demonstrated that 34% of deaths due to asthma are associated with poor adherence, further
emphasizing the significance of this problem (Royal College of Physicians, 2014). While various
interventional studies have been conducted on asthma medication adherence in children, many
studies are limited by the subjective nature of measurements for adherence (Desai and
Oppenheimer, 2011). A recent review found that a major limiting factor to clinical trials on
severe asthma is an inadequate assessment of adherence to maintenance therapy, resulting in
increased costs of trials as well as loss of statistical power (Mokoka et al, 2019). Self-reported
adherence to asthma medication, which is the most common way to assess adherence in research
studies, often overestimates medication adherence, making accurate assessment and intervention
difficult for clinicians (Bender et al, 2004, Burgess et al, 2008). In one study on inner-city
children, parents’ report on their child’s adherence to asthma medications was 85%, compared
with <25% when measured using pharmacy refill records (Otsuki et al, 2009). Outside of verbal
reports of adherence, questionnaires and diaries have also been employed to quantify and
potentially standardize adherence rates. However, these methods have also been shown to
overestimate actual adherence (Lam and Fresco, 2015). Other, more quantitative methods, such
as weighing canisters, dose counters on inhalers, and calculating medication possession ratio
using prescription refill data have all been studied as more objective ways of monitoring
adherence. However, the reported adherence from each method varies greatly, and none can
accurately measure true consumption of medications (Bender et al, 2000, Krishnan et al, 2012,
Sumino et al, 2013, Chung et al, 2000). Furthermore, physician judgment of patient adherence, a
key component to understanding disease management and optimizing treatment planning, is also
inaccurate (Pearce and Fleming, 2018).
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The usage of electronic monitoring devices (EMDs) offers a much more accurate and
objective view of adherence and has since been proposed as the possible “gold standard” for
measuring adherence due to its ability to offer time-sensitive information (Riekert and Rand,
2002). Studies that compare usage of EMDs against other forms of adherence measurements
consistently find that EMDs are more accurate and provide adherence rates that are much lower
than traditional means of measuring adherence (Bender et al, 2000; Riekert and Rand, 2002;
Pilcher et al, 2015). Though there is variability in the design and implementation of these EMDs,
most share common features, including a sensor to track actuations of inhalers, ability to track
doses using some form of sync function, and the ability to access adherence data for patients
and/or clinicians (Chan et al, 2015). One of the earliest EMDs introduced in clinical trial was
Doser, which was made commercially available in 1997. Despite clinical trials validating the
accuracy of this technology against other means such as canister weighing, as well as relative
low cost, the Doser is not commonly used in clinical practice today (Simmons et al, 1998;
O’Connor et al, 2004). Thus, despite clear advantages in measuring adherence rates, these
devices are not routinely used as part of interventions geared to improve medication adherence,
likely due to the cost associated with implementing such technology in the general public.
Additionally, lack of consistent research showing improved health outcomes have limited uptake
of insurance coverage for EMDs.
Recently, a growing body of literature on mobile technologies and remote patient
monitoring have been proposed as cost-effective ways of improving medication adherence in
chronic diseases, especially in children and adolescents (Van Gaalen et al, 2012; Mulvaney et al,
2013; Fedele et al, 2017). In this age group, self-management of asthma, which includes not only
adherence to medications, but also behaviors to monitor and prevent symptoms such as avoiding

4

asthma triggers, are often limited in scope (Bruzzese et al, 2012). Thus, technologic interventions
offer a potentially viable modality of behavioral change, especially in the management of
asthma. A number of studies have shown improvements in medication adherence through
incorporation of electronic reminders using text message reminders (Petrie et al, 2012; Britto et
al, 2017; Vasbinder et al, 2016). A pilot study done at the University of Cincinnati (n = 62)
looked at the effects of text message reminders over 3 months and found that there was an initial
2.75% increase in adherence compared to baseline as measured by EMDs. However, such a
difference was not sustainable by the end of the study (Britto et al, 2017). In a multicenter RCT,
another study looked at the utilization of short text message reminders on adherence to ICS in
children ages 4 - 11 over a span of 12 months. Text message reminders were sent to parents and
children, if they possessed a mobile phone, when missed doses were recorded using EMDs. The
study found that mean adherence over the total period of the study was higher in the intervention
vs control (69.3% vs 57.3%) as measured by EMDs. While there was a significantly higher rate
of adherence within the first six months, such high rates did not persist during the remainder of
the study period. Additionally, it found no differences in asthma control, quality of life, or
asthma exacerbations (Vasbinder et al, 2016). Another study conducted in New Zealand (n =
216) also looked at the effects of a text message reminder system on adherence to asthma
medications in adults aged 16 – 45. The study found that the intervention group had a higher
average rate of self-reported adherence when compared to control (57.8% vs 43.2%). A key
limiting factor to this study was the reliance on self-reported adherence. While these studies
show some promise in increasing adherence rates immediately after initiation of the intervention,
they demonstrated that simple reminder systems may be inadequate in addressing long-term
behavioral changes (Apter et al, 2012).
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While the concept of utilizing EMDs in management of asthma is not a new concept, the
integration of this technology into clinical practice has not been extensively studied. In studies
looking at the accuracy of utilizing inhaler trackers, they have shown consistently high accuracy
and reliability (Bonini and Usmani, 2018). In the pediatric population, studies have assessed
changes in asthma adherence after utilization of EMDs, often in concert with electronic
reminders and/or clinician feedback. However, most studies are small in study size and short in
clinical follow up. One study (total n = 26) assessed the usage if an EMD along with adherence
feedback and found that adherence was significantly higher in the intervention group (79% vs
58%) after four months. A study with a larger study size (n = 90) assessed the role of EMDs,
daily reminder alarms along with adherence feedback found significantly improved adherence in
the intervention group compared to the control (70% vs 49%) but did not find significant
differences in asthma control or lung function. Additionally, the EMD utilized was not able to
relay real-time adherence information for the participant or the participants’ parents until followup visits, when adherence information was reviewed for feedback with the clinician (Morton et
al, 2016). These studies show that while EMDs may increase adherence, more research is needed
to elucidate how EMDs can best be implemented in the clinical setting .
Inherently, the nature of adherence is multifaceted and effective treatment cannot merely
rely on reminder systems. Barriers to adherence may be “intentional”, such as having doubts or
concerns about treatment effectiveness or side effects, or “unintentional”, such as forgetfulness
and lifestyle barriers (ref). Reminder systems target the unintentional barriers to adherence, but
lack the educational intervention needed to target intentional barriers (Foster et al, 2014). While
mobile technology offers a unique way to address adherence in real-time, few studies have
looked at the effects of a combination of audiovisual reminders and feedback from medical
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providers on patient adherence in order to address intentional barriers to adherence. Feedback
alone has been shown to increase adherence, but such studies are limited by the size of study
sample (Onyirimba et al, 2003; Spaulding et al, 2012). In a systematic review of interventions
intended to improve adherence to inhaler medications in chronic lung disease, results indicate
that the combination of electronic monitoring with feedback was associated with significant
improvement in adherence (Pritchard and Nicholls, 2013). By combining mobile-based reminder
alarms with clinician feedback using real-time adherence from EMDs, both unintentional and
intentional barriers to adherence can be addressed. Real-time monitoring of adherence provides
greater insight regarding medication behaviors for physicians to better understand their patients,
creating both the educational opportunity to address both types of barriers to adherence through
clinical feedback. Additionally, this creates an opportunity to better direct care coordination
efforts in order to address socioeconomic barriers to adherence as well.
Non-adherence to asthma therapy is greatly influenced by socioeconomic factors
(Mazumdar et al, 2015). This is especially true in Connecticut, where childhood asthma
prevalence is consistently higher than that of the national average (11.3% compared to the
national average of 8.2% ref). In Connecticut, the highest prevalence of asthma is in the Hartford
community, consistent with national data that shows asthma prevalence is disproportionally high
among children from low-income and minority families as well as children that reside in innercity neighborhoods (Collaborative for Asthma Equity in Children, 2016; Nepaul et al, 2012;
Scope et al, 2016). Healthcare utilization due to asthma in children is also significant in this
population, resulting in 241.7 ED visits and 41.5 hospitalizations per 10,000 people, which is
significantly higher than the national average of 51.7 ED visits and 18.3 hospitalizations per
10,000 people (Collaborative for Asthma Equity in Children, 2016; CDC, 2015). In children with
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severe, poorly controlled asthma, poor adherence to ICSs is viewed as an important contributor
to poor asthma control resulting in further exacerbations requiring ED visits and hospitalizations.
Studies consistently show that lower socioeconomic status is associated with poorer asthma
control in children with asthma, with non-adherence adversely affecting those with low income
and education levels (Gong et al, 2014; Scope et al, 2016). Adolescents are particularly at risk
for non-adherence as asthma mortality in this group is approximately twice that of younger
children (Akinbami and Schoendorf, 2002). Self-management of asthma in adolescents is
limited, and barriers to achieving adequate control are multifaceted, with contributing factors
including lack of patient knowledge of disease, poor understanding of the benefits of medication,
forgetfulness, and negative attitude towards asthma (Holley et al, 2017). Currently, most
interventions designed to improve adherence in this age group are geared towards educational
and behavior modification interventions, including educational materials, individual and group
sessions, and follow-up phone calls (Bender et al, 2003). With the advent of EMDs, increasing
efforts are geared towards empowering adolescents to gain greater independence through
improved self-management of chronic diseases by implementing such technologies.
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METHODS:
Study Design This study was a prospective, randomized, controlled trial of children with persistent
asthma who are managed on daily ICSs. The goal of the study was to enroll 75 children,
randomized 2:1 into the intervention arm and the control arm, respectively. Such a sample size
was chosen due to the supply of EMDs (50) we had available to use for the study. The study
population consisted of children ages 8-17 years old with physician-diagnosed persistent asthma.
Participants needed to have been prescribed an ICS for at least one month using a pressurized
metered dose inhaler (pMDI) or dry powder inhaler that is compatible with the HeroTracker
EMD (Table 1; Figure 2A). The child or the parent/guardian, whoever was the main person who
administered the child’s medications, must have had a compatible smartphone with Bluetooth
capabilities. Patients had to be English or Spanish speaking. Patients with other co-morbidities
(including other types of chronic lung disease, chronic medical conditions such as congenital
heart disease) were excluded from the study. Patients who were or planned on becoming
pregnant were also excluded from the study.
Participants were recruited from the Connecticut Children’s Medical Center’s (CCMC)
Pulmonary clinic in Hartford, Connecticut. Participants were approached to participate during
regular visits to the pulmonary clinic. After verification of study eligibility based on inclusion
and exclusion criteria, the details of the study were discussed in detail with the child and parent
present at the visit. If the parent agrees for the child to participate, written consent from the
parent as well as assent from the participant were obtained by study personnel. Participants were
then stratified by age at the time of enrollment (8-13 years, 14-17 years), and randomly assigned
into the intervention or control group using computer-generated block randomization with block
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sizes of three, six, or nine. Due to the nature of the study, the participants, research personnel and
the clinicians were not blinded.
After enrollment, each participant was followed at 3 months (+/- 20 days) and at 6
months (+/- 20 days) (Figure 1). The follow up appointments were meant to correlate with
regularly scheduled follow up appointments for participants.

Figure 1. Study Design.
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Daily Control
Advair Diskus (100/50 mg), (250/50 mcg),
(500/50 mcg)

Dulera 100/5 mcg and 200/5 mcg

Advair HFA (45/21 mcg), (115/21 mcg),
(230/21 mcg)

Duolin HFA 20 mcg

AeroSpan 80 mcg (60 count) and (120 count)

Flovent 44 mcg, 110 mcg and 220 mcg

Alvesco 80 mcg and 160 mcg

Flovent Diskus 50 mcg, 100 mcg and 250
mcg

Asmanex HFA

Foratec HFA 12 mcg

Asthavent 100 mcg

Foster 100/6 mcg

Atimos 12 mcg (50 count), (100 count) and
(120 count)

Ipvent HFA 40 mcg

Beclate HFA 50 mcg, 100 mcg, 200 mcg

QVAR 40 mcg, 80 mcg

Budeflam 100 mcg

Serevent Diskus

Ciclovent 160 mcg

Seroflo 50 mcg,125 mcg, 250 mcg

Clenil 50 mcg, 100 mcg, 200 mcg, 250 mcg

Symbicort 80/4.5 mcg, 160/4.5 mcg, 400/12
mcg
Rescue

Atrovent HFA
ProAir HFA
Proventil HFA
Ventolin HFA 60 count, 200 count
Xopenex HFA 80 count, 200 count
Table 1. Pressurized metered dose inhalers (pMDI) compatible with the
HeroTracker EMD.
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Intervention Group:
The intervention arm consisted of a mobile-based platform produced by Cohero Health®
that consists of: 1) BreatheSmart mobile application, which tracks medication usage and sends
real time reminders based on individual treatment plans, 2) HeroTracker sensor, which is an
EMD that counts actuation of the inhaler it is attached to, and is synced to the BreatheSmart app
via Bluetooth technology, and 3) CoheroConnect, a HIPPA-compliant, web-based portal that
allows researchers and clinicians, to monitor adherence in real-time (Figure 2). Using these three
products, participants received alerts through their BreatheSmart app to take their daily
preventive ICSs, which were typically given once daily or twice daily. Participants were given
two HeroTracker sensors, one for the controller (ICS) and another for the rescue (albuterol)
MDIs, allowing the app to track actuation for both types of inhalers. Study personnel along with
clinicians were trained on how to monitor adherence using CoheroConnect. If randomized into
the intervention arm of the study, the participant and/or the parent (whomever was the main
person managing the participant’s daily ICS) were provided with training on how to utilize the
BreatheSmart app at the initial intake visit. Participants were told to download the app while in
the office and were instructed on how to sync their HeroTrackers to their phones. If participants
were unable to do this in the office, study personnel contacted the participants after the visit to
ensure participants did not have any issues with the installation process.
At the 3-month follow up visit, physicians are asked to review adherence data since the
participant’s previous visit via CoheroConnect and provided adherence feedback to the
participant. Each feedback discussion by the physician was personalized to the participant and
the participant’s level of adherence.
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A)

B)

Figure 2. Components of BreatheSmart Intervention. A) HeroTrackers – wireless
Blue-tooth enabled inhaled sensors that are attachable to pMDI (left) and diskus (right) inhalers.
B) CoheroConnect– a web-based platform for clinicians to monitor participants’ adherences.

Control Group:
Control participants were provided standard care as they would be given at a specialized
clinic. They were not provided access to the BreatheSmart app, CoheroConnect, or an EMD.
Participants were seen at their standard asthma clinic for regular follow up care.
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Assessments:
At each visit (initial enrollment, 3-month follow up, and 6-month follow up), the
following assessments will be performed:
•

Intake assessment:
o Demographics:
§

Age of the participant

§

Ethnicity as defined by the participant and/or parent, characterized into
“African American”, “White”, “Hispanic, non-Puerto Rican”, “Puerto Rican”
or “Other”. During analysis, this was recoded into “African American”, “NonHispanic White”, with “Hispanic, non-Puerto Rican” and “Puerto Rican”
recoded as “Hispanic”.

§

Gender as defined by the participant, measured dichotomously as “Female” or
“Male”

§

Self-reported family income, characterized as “<$15,000”, “$15,000$29,999”, “$30,000 – $49,999”, and “>$50,000”. During analysis, this was
recoded into “<$30,000” or “>$30,000”

§

Type of insurance, confirmed using electronic medical records

o Medication list, and other potential comorbidities
o Asthma therapy – ICS prescribed, dosage, and frequency of dosage
o Asthma severity (physician confirmed)
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o Asthma Control Test (ACT) score - The Asthma Control Test (ACT) is used to assess
asthma control within the past four weeks – a score <= 19 indicates poorly controlled
disease (Liu et al, 2006)
o Three methods of assessing for adherence:
§

Test of the Adherence to Inhalers (TAI) – a validated questionnaire to assess
for adherence (Plaza et al, 2016)

§

Self-reported adherence, which was reported by the participant and/or parent
as the “number of doses missed per week”

§

Pharmacy refill history over the past 6 months prior to enrollment

o Any ED visits in the past year, measured dichotomously as “Yes” or “No”
o Any hospitalizations in the past year, measured dichotomously as “Yes” or “No”
o Any oral steroid use in the past year, measured dichotomously as “Yes” or “No”
o Pulmonary Function Test (PFTs), including Forced Expiratory Volume (FEV1) and
Fractional exhaled Nitric Oxide (FeNO), which were confirmed using electronic
medical records.
§

FEV1% <= 80% indicates “Not well controlled” asthma based on National
Heart, Lung, and Blood Institute (NHLBI) guidelines (National Asthma
Education and Prevention Program, 2007)

§

FeNO is a measure of responsiveness to anti-inflammatory therapy, but is not
clinically indicated for every patient. FeNO > 50 ppb (>35 ppb in children <
12 years of age) indicates low-adherence or inadequate response to ICS based
on American Thoracic Society (ATS) guidelines (Dweik et al, 2011)
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•

Follow-up assessment:
•

ACT score

•

TAI

•

Self-reported medication adherence

•

Pharmacy refill history since last visit

•

Number of ED visits since last visit

•

Number of hospitalizations since last visit

•

Number of oral steroid uses since last visit

•

PFTs, including FEV1 and FeNO

•

For intervention group –
o Any technical issues related to the BreatheSmart platform
o For those who completed six months in the study, participants were asked to
answer a 5-item questionnaire which was scored on a 5-point semantic
differential scale (1 = strongly disagree, 5 = strongly agree) which asked about
topics such as acceptability of use, perceived effects on asthma control, and
usefulness of physician feedback:
§

“I would be happy to continue using my BreatheSmart app and
HeroTracker”

§

“I feel more control of my asthma now”

§

“Knowing when to take my asthma medication is easy”

§

“I would recommend using this to other people I know with asthma”

§

“Going over how often I take my asthma medication with my doctor
was helpful”
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Study Outcomes
The primary outcome for this study was medication adherence as measured by pharmacy
refill. This was used because this is the most reliable means of measuring adherence between the
control and intervention groups. Medication adherence as measured by pharmacy refills was
calculated using Proportion of Days Covered (PDC), a commonly used method of calculating
adherence that is defined as a ratio of sum of unique days supplied based on refills over the total
number of days in the period that is assessed (Choudhry et al, 2010). PDC has been shown to be
more accurate at assessing adherence when compared to other methods (Martin et al, 2009). For
the baseline adherence measurement, the PDC was assessed over a 6-month period prior to the
enrollment date. The 6-month PDC was calculated over the 6-month period from the date of
enrollment. Change in PDC was calculated as the difference between the 6-month PDC and
baseline PDC.
A secondary outcome for this study was adherence as measure by EMD. Average
adherence based on EMD is calculated using the average of daily adherence rates as recorded by
the EMDs. Another secondary outcome is the Asthma Medication Ratio (AMR), which is a
National Committee for Quality Assurance measurement for patients with persistent asthma.
Using pharmacy refill data, AMR is calculated as the ratio of controller refills over the sum of
controller refills and short-acting beta-agonist refills. Studies have shown AMR < 0.5 is
associated with increased ED visits and hospitalizations as well as poorer quality of life (Beck et
al, 2015; Andrews et al, 2013). Other secondary outcomes, such as ACT score, PFTs, TAI, as
well as number of ED visits, hospitalizations, oral steroid uses, were evaluated but not presented
in this analysis due to low number of responses.
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Study Timeline:
The original study protocol was submitted for full board review through the Institutional
Review Board (IRB) at Connecticut Children’s Medical Center on April 10, 2017. The protocol
was approved by the IRB board on July 13, 2017. Recruitment started in January, 2018.
Recruitment took place at the Connecticut Children’s Medical Center pulmonary clinic in
Hartford, Connecticut.

Data and Analysis:
Because this is an ongoing study, we included in the analysis all participants who had
been enrolled for six months as of February 1, 2019.
Data analysis was based on an intention to treat model. Medication adherence based on
pharmacy refill was calculated using PDC, for which the calculation has been defined elsewhere
in literature (Choudhry et al, 2010). Medication adherence rates based on EMD was calculated
over the span of the 6-month period, subdivided into morning and night doses, and recorded as a
percentage. This was calculated as the ratio of doses actuated as recorded by the EMD over the
number of doses prescribed x 100. The daily adherence was capped at 100%, to avoid falsely
increased values due to dose dumping. The overall six monthly figure was a mean of each
daily %. For example, if a child was prescribed two puffs twice a day, and only took two puffs
on the first day, six puffs on the second day, four puffs on the third day, and two puffs on the
fourth day, the daily adherence would be 50%, 100%, 100%, 50%, respectively. The average
adherence for this time period would be 75%.
Between-group comparisons of adherence rates based on PDC at baseline and at six
months were conducted using two-sample independent t-tests. To account for differences in
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baseline adherence, changes in adherence from baseline to six months were compared between
groups using a two-sample independent t-test. Average EMD adherence rates for the first 30
days, 90 days, and 180 days of the study period were calculated for the intervention group.
Additionally, AM and PM EMD adherence rates were calculated and compared using a paired ttest. Changes in AMR (<0.5 or ≥0.5) from baseline to 6-months within groups were tested by
McNemar test. Chi-square tests were applied to compare AMR between groups at baseline and at
six months. All the statistical analyses were performed in SPSS. A p-value smaller than 0.5 was
considered statistically significant.

RESULTS:
From January 2018 through February 2019, 116 individuals were approached and
screened for eligibility to participate. Forty-three (37%) did not meet inclusion criteria and 19
(16%) were not interested. A total of 53 participants (36 intervention, 16 control) were enrolled
between January 2018 and February 2019. A total of 41 participants (29 intervention, 12 control)
who had been enrolled for six months were included for this analysis. Within the control group,
only four participants (33%) completed a 3-month follow up, and only five participants (42%)
completed a 6–month follow up visit. Within the intervention group, only 13 participants (45%)
completed a 3-month follow-up, and only 16 participants (55%) completed a 6-month follow-up,
(Figure 2). This occurred due to either participants not attending or cancelling scheduled
appointments. For those without a 3-month follow-up in the intervention group, no physician
feedback was provided.
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Figure 2. CONSORT diagram (updated on 2/1/2019). Participants who were enrolled in
the study for 6 months at the time of analysis are included for this analysis.

Demographics:
Demographic characteristics of participants analyzed are shown in Table 2. Participants
were on average 12.7 (SD = 3) years old, 49% were Latino, 29% were Non-Hispanic White, and
22% were African America. The majority of participants (78%) utilized public insurance and
slightly more than half reported a family income of less than $30,000. The majority of
participants had moderate or severe persistent asthma (44% and 51%, respectively).
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Total

Control

Intervention

P value

(n=41)

(n=12)

(n=29)

Age (years)

12.7 (3)

12.5 (2.9)

12.7 (3.1)

0.83

Sex (Female)

23 (55%)

6 (50%)

17 (59%)

0.43

African American

9 (22%)

4 (33%)

5 (17%)

0.53

Latino

20 (49%)

5 (42%)

15 (52%)

Non-Hispanic White

12 (29%)

3 (25%)

9 (31%)

32 (78%)

11 (92%)

21 (72%)

0.18

<$30,000/year

22 (54%)

8 (67%)

14 (48%)

0.28

>=$30,000/year

19 (46%)

4 (33%)

15 (52%)

Mild persistent

2 (5%)

1 (8%)

1 (3%)

Moderate Persistent

18 (44%)

5 (42%)

13 (45%)

Severe Persistent

21 (51%)

6 (50%)

13 (52%)

Race/Ethnicity

Public Insurance
Reported Family Income

Asthma Severity
0.80

Table 2. Demographics of study participants. Data presented as mean (SD) or N (%).

At baseline, participants had a high disease burden of asthma, as indicated by high rates
of ED visits (56%), hospitalizations (34%), and oral steroid usage (80%) in the last year (Table
3). Twenty-two (51%) of the participants had ACT scores <= 19, indicating poor control.
Average FEV1% was 90.9%, with 31% of total participants having “Not well controlled” asthma
based on NHLBI guidelines. For the participants with FeNO (n= 13), average FeNO level was
51.4 ppb, with 50% of participants showing high levels of FeNO as defined by ATS guidelines
(Dweik et al, 2011). At baseline, 66% of patients scored in the “poor” adherence category based
on TAI. When asked specifically asked the question “number of missed doses per week”,
adherence per patient report was 85.8%.
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Total (N=41)

Control (N =

Intervention

P

12)

(N=29)

value

23 (56%)

7 (58%)

16 (55%)

0.57

14 (34%)

3 (25%)

11 (38%)

0.34

32 (80%)

8 (73%)

24 (83%)

0.38

22 (51%)

9 (75%)

13 (45%)

0.08

12 (31%)

1 (10%)

11 (38%)

0.13

(n = 10)

(n = 29)

2 (50%)

4 (50%)

(n=4)

(n=8)

85.8% (16)

90% (12)

84% (18)

0.65*

Good

6 (15%)

2 (17%)

4 (14%)

0.94

Intermediate

8 (20%)

2 (17%)

6 (22%)

Poor

27 (66%)

8 (66%)

19 (66%)

Any ED visits in the last year (N
(%))
Any hospitalizations in the last
year (N (%))
Any oral steroid use in the last
year (N (%))
Baseline ACT score ≤19 (N (%))
Lung function
FEV1 <= 80% (N (%))
High FeNO (N (%))
Self-reported adherence (mean
(SD))

6 (50%)

0.73

Baseline TAI (N (%))

Table 3. Baseline characteristics of participants. ACT = Asthma control test (≤19
indicates uncontrolled asthma). FEV1% = Forced expiratory volume in 1 second, % of predicted.
FEF 25-75% = Forced expiratory flow at 25-75%, % of predicted. FeNo = Fractional exhaled
nitric oxide. TAI = Test of the Adherence to Inhalers. *Due to negative skewness of results, nonparametric Mann-Whitney U test was used to test for null-hypothesis.
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Primary Outcome
Adherence rates at six months based on PDC did not differ significantly between the
control and intervention groups (Figure 3, p = 0.21). The average adherence in both intervention
and control groups decreased from baseline to six months. At baseline, the mean adherence
based on pharmacy refill for the control group and intervention group was 42% and 50%,
respectively (p = 0.37). At six months after enrollment, the mean adherence for the control group
and intervention group was 31% and 41%, respectively (p = 0.21). The adherence for the control
group dropped on average by 11%, which was not significantly different from 9% for the
intervention group (p = 0.83) (Table 4).

Figure 3. Adherence based on pharmacy refill.
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Control (n=12)

Intervention
(n=29)

P value

Baseline

42% (24)

50% (27)

0.37

6 months

31% (20)

41% (27)

0.21

Change in PDC (mean
(SD))

- 11% (22)

- 9% (32)

0.83

PDC (mean (SD))

Figure 4. Mean adherence rates based on pharmacy refill.

Secondary outcomes:
Average adherence over the six months for the intervention group was 27.4% based on
EMD. Higher average adherence was obtained in the initial 30 days after enrollment (56.1%),
but this declined over time during the 6 month study period (Table 5). Of note, out of the 29
patients in the intervention group, only 26 participants were assessed as three participants never
used the EMD. Interestingly, when average daily adherence was plotted over time, there was an
initial high rate of adherence of > 70% in the first week of the study, but this number dropped
drastically after the first week (Figure 4). When comparing average adherence in the first month
vs the overall adherence over the six months of the study, there was a statistically significant
drop in adherence from 56.1% to 27.4% (p = 0.00). When daily adherence was further
subdivided into AM and PM doses, there was no difference in adherence to the AM or PM doses
(Table 5, p = 0.22 for the 180-day adherence).
AMR did not differ significantly between intervention and control groups at baseline or
at six months (Table 6, p = 0.73 and p = 1.00, respectively). McNemar Test also did not show
any statistically significant changes in AMR from baseline to six months within the intervention
group or the control group (p = 0.78 and p = 0.69, respectively).
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Average Daily Average AM Average PM P-value*
Adherence

Adherence

Adherence

30 Day Adherence (mean, ±SD)

56.1% (35.1)

55.6% (34.7)

54.2% (36.6)

0.64

90 Day Adherence (mean, ±SD)

41.2% (32.5)

39.2% (31.8)

42.4% (35.6)

0.40

180 Day Adherence (mean, ±SD)

27.4% (27.4)

31.8 (33%)

26.2% (27.1)

0.22

*p-value is calculated as difference between AM and PM adherence rates

Average Daily Adherence

Table 5. Average, AM, and PM adherence rates based on EMDs.

100%
80%
60%
40%
20%
0%
0

50

100

Day(s) after enrollment
Figure 4. Average daily adherence based on EMD.

25

150

200

Intervention (N=29) Control (N=12) Chi-square test
Baseline AMR (N, %)
< 50%

12 (41%)

6 (50%)

>= 50%

17 (59%)

6 (50%)

< 50%

10 (35%)

4 (33%)

>= 50%

19 (65%)

8 (67%)

0.73

6 – month AMR (N, %)
1.0

Table 6. Asthma Medication Ratio (AMR).

Device Performance and Patient Acceptability
Out of the 21 participants in the intervention group who received follow-up visits, one
participant never utilized the EMD due to changes in medication therapy. Out of the 20
participants who utilized the EMD, 13 (65%) participants experienced technical issues. Seven
out of the 13 participants experienced technical issues related to syncing problems between the
EMD and the BreatheSmart app.
Out of the 29 participants in the intervention group, 16 participants completed the 5-item
questionnaire on patient acceptability of the intervention at their 6-month follow up visit. Table 7
summarizes results from this questionnaire. Patient satisfaction with the intervention was high,
with high median scores for Questions 1 and 4 (median scores = 5 and 4, respectively). Perceived
control of asthma symptoms (Questions 2 and 3) also had relatively high scores (median score =
4 for both), although the mean was less than 4 for Question 2. Lastly, patient acceptability of
physician feedback was also high (median score = 4).
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Question
1) I would be happy to continue using my
BreatheSmart app and HeroTracker

N

Mean (SD) Median (Q1, Q3)

15

4.5 (0.7)

5.0 (4.0, 5.0)

2) I feel more control of my asthma now

15

3.9 (1.1)

4.0 (3.0, 5.0)

3) Knowing when to take my asthma medication
is easy

15

4.1 (1.0)

4.0 (3.0, 5.0)

4) I would recommend using this to other people
I know with asthma

15

4.3 (0.8)

4.0 (4.0, 5.0)

5) Going over how often I take my asthma
medication with my doctor was helpful

16

4.0 (1.1)

4.0 (3.8, 5.0)

Table 7. Patient acceptability of intervention.

DISCUSSION:
In this preliminary analysis of data from a part of a larger randomized, controlled trial,
we did not see any significant differences in adherence rates between the control and intervention
groups after six months. Additionally, there was no statistically significant change in adherence
between the control and intervention group. Interestingly, adherence rates for both groups fell
from baseline to 6 – months. Additionally, we did not demonstrate any significant changes in
AMR, a measure of asthma control, within the intervention group. From our data obtained from
EMDs, while we did see an initial high rate of adherence within the first seven days of
intervention, this rate was not sustainable after 180 days.
Multiple factors may have contributed to the decrease in adherence for both groups. Both
groups lacked adequate clinical follow-up. The majority of the participants in both the control
and intervention groups did not have a follow-up at three and six months after enrollment. Since
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our follow-up visits are meant to align with regularly scheduled clinic visits, this meant that the
majority of children in both groups did not receive clinically-indicated follow up visits to
adequately monitor their asthma control. For the intervention group in particular, this meant that
55% of participants did not receive physician feedback on adherence, a vital part of our
intervention (Figure 2). Additionally, asthma is a highly seasonal disease. Most asthma patients
are highly symptomatic during school months (September to June). Due to the timeline of this
study, the majority of participants were enrolled prior to June 2018. This means baseline
adherence was assessed over more symptomatic months, while the majority of intervention
months occurred over less symptomatic summer months. During this time, children may be less
adherent due to decreased symptoms and may be less likely to attend clinical follow-up visits
due to inconsistent schedules during the summer months. This decrease in adherence over time
for the control group is consistent with results from previous adherence interventional studies
that have also monitored asthmatic children over study periods of six months (Morton et al,
2017; Charles et al, 2007).
Within the intervention group, we did not see any significant, sustainable improvements
in adherence. While other studies have demonstrated increased adherence rates for intervention
groups, many had continual monitoring of participants with prompt interventions (e.g. calling,
text-messaging) when there were recordings of non-adherence registered from the EMDs. Since
we wanted to assess whether this technology would be adaptable to this high-risk pediatric
population, lack of close monitoring could be one of the explanations for the statistically
significant fall in adherence after the initial seven to 30 days after enrollment. Technical
difficulties could also have contributed to the lack of change with intervention. The high rate of
technical difficulties (65%) amongst the intervention group indicates that this could have been a
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barrier for implementation of technology. In particular, syncing issues seemed to have been a
major part of the reason why these technical issues occurred. Though the tracker is supposed to
store any doses that were actuated but not synced with the phone, it is unclear if any doses may
have been missed due to syncing issues. Additionally, the concept of “app fatigue” is evidenced
by the increase in usage of mobile phone apps across all age-groups (Zhao et al, 2016). Despite
this, a study showed that 25% of people will abandon an app after one use, and 62% of users will
use an app less than 11 times (Perez, 2016). For an intervention where efficacy is highly
dependent on sustainable usage of the phone app, this could have been a major limiting factor for
sustainable usage of the intervention, as evidenced by the steep drop in average daily adherence
after the first week. Lastly, while physician feedback was meant to be individualized in nature in
order to address both intentional as well as non-intentional barriers to adherence, it was
impossible to monitor for consistencies in the quality of feedback that participants received at
their follow-up appointments. We did not assess for variability in clinician approach to
interpreting adherence data on the CoheroConnect dashboard along with the role that adherence
feedback played in clinical decision-making, which made standardization of clinician feedback
difficult. These factors could have all contributed to the lack of sustainable rates of adherence in
this intervention group.
One of the key aspects of this study was to assess for the feasibility of implementing this
intervention in the clinical setting. As evidenced by the high variability in the adherence results
using different modes of assessing for adherence in this study (e.g. questionnaire format using
TAI, pharmacy refill data calculated as PDC, self-report, and adherence based on EMD), lack of
consistent and accurate means of measuring adherence can hinder clinical decision making for
physicians. At baseline, self-reported rates of adherence were consistently high (>80%), yet rates
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obtained using pharmacy refill data showed adherence rates were on average less than 50%. This
is consistent with published rates of asthma adherence in children (Sherman et al, 2000; Otsuki et
al, 2009). While we cannot compare EMD adherence rates at baseline, the average EMD
adherence rate at the end of the study was much lower than the average adherence rate obtained
using PDC (27.4% vs 41%). Here, our study is consistent with other studies that have also
demonstrated EMD adherence rates to be lower than the rates obtained using pharmacy refill and
self-report (Bender et al, 2000; Jentzsch et al, 2009). Based on our data, due to the
aforementioned technical issues, it is difficult to infer whether adherence rates as measured by
EMDs are more accurate than other modes of assessing adherence. However, this does show that
EMDs are able to relay a level of detail on patients’ health behaviors that clinicians were never
able to see using the other methods of assessing adherence. For example, using EMDs, we were
able to delineate between AM and PM doses. While we did not demonstrate any differences in
missed doses based on timing of the doses, this shows that this technology can offer such
explanation for health behaviors over time. Being able to understand patterns in health behaviors
is the first step in being able to counsel and modify behaviors.
This study also demonstrates that there may be barriers to medication adherence that
cannot be addressed using EMDs, especially in a high-risk, high-disease burden community. Our
study participants were mostly made up of ethnic minorities of low-socioeconomic status with
high asthma severity. The burden of disease in this study group was high, as indicated by the
high rates of ED visits, hospitalizations, and oral steroid usage. In such a population, a
multidisciplinary approach including care coordination efforts, is vital in addressing
psychosocial and environmental factors (Burke et al, 2016). Factors such as parental stresses as
well as childhood stress related to residence in low-income, inner-city communities negatively
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influences asthma self-management, and is associated with morbidity and non-adherence (Butz
et al, 2014). Additionally, as evidenced by our low return rate for follow-up visits, there may be
additional issues related to access to care that could not have been addressed in this study. These
factors are vital aspects of preventive care, especially in inner-city children with asthma (Butz et
al, 2014). While EMDs may be able to address intentional non-adherence, and feedback may be
able to tackle some aspects of non-intentional non-adherence, without consistent care
coordination efforts, we cannot effectively address environmental factors that greatly influence
asthma severity and disease burden. Additionally, there are practical considerations when
addressing socioeconomic factors in the clinical setting. With increasing time restraints put on
clinicians, it is increasingly difficult to effectively address both medical as well as social issues
that patients may face. While the pulmonary clinic at Connecticut Children’s Medical Center is a
specialty clinic, there are no consistent care coordination efforts in the form of care coordinators
given to every child with asthma, limiting the resources that patients have access to. This, along
with time limitations, could have greatly influenced the quality of feedback that participants
received.
Overall, despite lack of change in adherence seen in the intervention group, we saw that
patient acceptability of the intervention was high after six months of use. Participants reported
willingness to continue use as well as recommending use to others. Additionally, participants
reported perceived control of asthma symptoms, and responded favorably to physician feedback.
Of course, similar to other studies, our acceptability questionnaire was not validated (Chan et al,
2016; Foster et al, 2012). We did not control for whether participants or parents answered the
questionnaire. If the parent answered, it is uncertain the response was from the person who
managed the participant’s asthma care. For participants, young children could have had difficulty
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comprehending the language used in the questionnaires, and older children could have refused to
complete questionnaires or provided inaccurate answers. Thus, further validation testing of the
questions in this questionnaire would be needed.
Several other limitations existed for this study. First, we did not have a study arm that
only had EMDs with no phone app or feedback intervention. This made it difficult to compare
EMD data between control and intervention groups. Additionally, we did not have a period of
time with the EMD to accurately measure baseline adherence. Thus, our only way of measuring
adherence that was consistent between groups was based on pharmacy refill data, which has been
shown to be less accurate than EMDs (Jentzsch et al, 2009). Additionally, we did not control for
who the app was given to, only that the app was given to whomever managed the child’s asthma
at home. Thus, the intervention was not given to consistently address self-management of
asthma, which means other parental factors could have influenced usage of the EMD and app.
Another limitation to the study was the fact that we could not analyze any of the rescue data from
the rescue EMD given to participants. We found that very few participants recorded any rescue
inhaler use, which was the reason this data was not included for analysis. This was unlikely due
to lack of rescue inhaler use, as evidenced by the poorly controlled asthma in our participants.
This could be due to the fact many patients have multiple rescue inhalers – one for home, one for
school - meaning we could not fully capture the full extent of use with only one tracker given to
participants. Lastly, as this analysis was preliminary, the study cohort analyzed represents only a
portion of all the participants in the trial. Further follow-up and recruitment would likely account
for the seasonality of disease mentioned previously, as well as a better understanding of how this
intervention could affect pediatric asthma.
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CONCLUSION:
In conclusion, this is the first study to our knowledge that looks at the feasibility as well
as acceptability of using EMDs along with clinician feedback in a high-risk, high disease-burden
community like Hartford, Connecticut. Our preliminary data did not show any significant
changes to adherence after implementation of this intervention in children with persistent
asthma. However, patient acceptability of EMDs was high despite technical issues related to the
device which still needs to be resolved prior to use in the clinical setting. Overall, this study
reinforces the fact that non-adherence to asthma controller medications in children remains
suboptimal, especially in low-socioeconomic communities. Significant barriers to adherence still
exist that may not be adequately addressed with EMDs alone, but EMDs could potentially offer
greater insight into children’s health behaviors. Thus, further research as well as follow-up on the
rest of the cohort of participants in this study is needed in order to elucidate the role that EMDs
can play in the management of asthma in children and adolescents.
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